Articles tagged "Immunosuppression"

2017 American Transplant Congress
Emerging Safety and Tolerability of Obinutuzumab, a Type 2 Anti-CD20 Monoclonal Antibody for the Desensitization of Renal Transplant Candidates.
R. Redfield,¹ S. Jordan,² T. Schindler,³ H. Tran,⁴ C. Looney,⁴ C. Green,⁴ A. Morimoto,⁴ R. Rajwanshi,⁴ M. Cascino,⁴ P. Brunetta,⁴ D. Borie.⁴
¹University of Wisconsin, Madison; ²Cedars-Sinai Medical Center, Los Angeles; ³F. Hoffmann-La Roche AG, Basel, Switzerland; ⁴Genentech, Inc., South San Francisco
Background: Rituximab has limited efficacy for desensitizing allosensitized patients (pts) with end-stage renal disease (ESRD) and enabling kidney transplantation (KTx), however, tissue B-cell depletion is…
2017 American Transplant Congress
Down but Not Out: Leucopenia Can Be Safely Treated with Reduction in Immunosuppression without Increasing Risk to the Kidney Allograft.
A. Gilbert,¹ A. Vergottini,¹ A. Karabala,¹ M. Grafals,¹ B. Javaid,¹ J. Moore,¹ J. Verbesey,² P. Abrams,² S. Ghasemian,² M. Cooper.²
¹Department of Medicine, Medstar Georgetown Transplant Institute, Washington, DC; ²Department of Surgery, Medstar Georgetown Transplant Institute, Washington, DC
IntroductionLeucopenia is a growing problem with increasing immunosuppression (IS) in kidney transplantation. Reducing IS in the face of leucopenia is a concern due to the…
2017 American Transplant Congress
Incidence of Donor-Specific Anti-HLA Antibodies in Non-HLA Sensitized Patients Given Tacrolimus Once or Twice Daily During the First Two Years Post-Transplantation.
N. Kamar, V. Hajj, I. Ferrandiz, E. Younes, L. Esposito, A. Hébral, A. Del Bello.
Department of Nephrology and Organ Transplantation, Toulouse University Hospital, Toulouse, France
Donor-specific anti-HLA antibody (DSA)-mediated rejection (AMR) is a main cause of graft loss after kidney transplantation. Non-adherence is a risk factor for AMR and graft…
2017 American Transplant Congress
Conservative Management of Pneumatosis Intestinalis After Pediatric Liver Transplantation.
R. Hendrickson, J. Ryan, L. Dandridge, W. Andrews, J. Daniel, R. Fischer, D. Rivard.
Transplant Surgery, Developmental and Behavior Sciences, Hepatology and Radiology, Children's Mercy Hospital, Kansas City, MO
BACKGROUND: Pnuematosis intestinalis (PI), characterized by gas in the bowel wall, is a rare pathologic finding in pediatric liver transplantation (PLT) recipients. PI has been…
2017 American Transplant Congress
A Novel MyD88 Inhibitor Attenuates Allograft Rejection in Heterotopic Tracheal Transplantation in Mice.
M. Yang, X. Zhang, G. Chen, Z.-C. Ding, Y. Miao, Y. Yang, P. Zhou.
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technolog; Key Lab of Ministry of Education & Ministry of Health of China, Wuhan, Hubei, China
Background: Obstructive bronchiolitis (OB) characterized by chronic rejection, is the main complication after lung transplantation which limits the long-term survival of the recipients. Innate immune…
2017 American Transplant Congress
Tacrolimus Dose Variability, CYP3A5 Genotype, and Acute Rejection in African American and European American Kidney Transplant Recipients.
S. Seibert,¹ D. Schladt,² B. Wu,³ W. Guan,³ C. Dorr,^2,7 D. Berglund,¹ R. Remmel,⁴ A. Matas,⁵ R. Mannon,⁶ A. Israni,^2,7 W. Oetting,¹ P. Jacobson,¹ For the DeKAF Genomics Investigators.
¹Dept of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota (UMN), Mpls, MN; ²Chronic Disease Research Group, Minneapolis Medical Research Foundation, Mpls, MN; ³Division of Biostatistics, School of Public Health, UMN, Mpls, MN; ⁴Dept of Medicinal Chemistry, College of Pharmacy, UMN, Mpls, MN; ⁵Division of Transplantation, Dept of Surgery, School of Medicine, UMN, Mpls, MN; ⁶Dept of Nephrology, University of Alabama, Birmingham, AL; ⁷Dept of Nephrology, Hennepin County Medical Center, School of Medicine, UMN, Mpls, MN
Background: Poor immunosuppression with tacrolimus (TAC) after kidney transplantation contributes to the development of toxicity and loss of efficacy. We aimed to associate intra-patient TAC…
2017 American Transplant Congress
Determinants of Successful Use of Sirolimus in Renal Transplantation.
M. Naik,¹ W. Gwinner,² W. Arns,³ E. Basic,¹⁰ K. Budde,¹ F. Diekmann,⁴ M. Fischereder,⁵ J. Goßmann,⁶ K. Heller,⁷ N. Heyne,⁸ J.-S. Jürgensen,¹ C. Morath,⁹ U. Riester.¹⁰
¹GSSG, Berlin, Germany; ²GSSG, Hannover, Germany; ³GSSG, Köln, Germany; ⁴GSSG, Barcelona, Spain; ⁵GSSG, München, Germany; ⁶GSSG, Frankfurt, Germany; ⁷GSSG, Erlangen, Germany; ⁸GSSG, Tübingen, Germany; ⁹GSSG, Heidelberg, Germany; ¹⁰GSSG - Pfizer, Berlin, Germany
Sirolimus (SLR) is an established component in the immunosuppressive treatment after renal transplantation.The side effects of SLR differ from other immunosuppressants and may limit its…
2017 American Transplant Congress
CMV and BK Virus Infections in Kidney Transplant Recipients Receiving an mTORi-Based Regimen versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis.
B. Tanios,¹ S. Mallat,¹ H. Itani,¹ T. Lotfi,¹ S. Gabardi,² E. Akl,¹ J. Azzi.²
¹Division of Nephrology, American University of Beirut Medical Center, Beirut, Lebanon; ²Renal Division, Harvard Medical School, Boston
The objective of this systematic review is to compare the incidence of CMV and BK virus infections in kidney transplant recipients receiving an mTORi-based as…
2017 American Transplant Congress
Everolimus Is Associated with Less Weight Gain Than Tacrolimus Two Years Following Liver Transplantation: Results of a Randomized Multicenter Study.
M. Charlton,¹ M. Rinella,² D. Patel,³ K. McCague,³ J. Heimbach,⁴ K. Watt.⁴
¹Intermountain Medical Center, Salt Lake City; ²Northwestern University, Chicago; ³Novartis Pharmaceuticals Corp., East Hanover; ⁴Mayo Clinic, Rochester
Weight gain after liver transplant may lead to post-transplant complications, and is a risk factor for post-transplant metabolic syndrome (PTMS), cardiovascular events, and renal insufficiency.…
2017 American Transplant Congress
Higher Tacrolimus Blood Levels Predict Better Graft Survival in Kidney Recipients with De Novo DSA.
M.-A. Béland,¹ R. Noël,¹ I. Côté,¹ I. Lapointe,¹ E. Wagner,² J. Riopel,³ E. Latulippe,³ O. Désy,¹ S. Béland,¹ I. Houde,¹ S. De Serres.¹
¹Renal Division, CHU de Quebec, Laval University, Quebec City, QC, Canada; ²Immunology and Histocompatibility, CHU de Quebec, Laval University, Quebec City, QC, Canada; ³Pathology, CHU de Quebec, Laval University, Quebec City, QC, Canada
Background: De novo anti-HLA donor specific antibodies (dnDSA) are associated with poorer outcomes in kidney transplant recipients. Nonetheless, their monitoring post transplant is not widespread,…